Patent application number | Description | Published |
20090036353 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers - Insulin conjugated with structurally well defined, bifurcated and trifurcated polymers can be use by pulmonary delivery for systemic absorption through the lungs to reduce or eliminate the need for administering other insulins by injection. | 02-05-2009 |
20090069215 | Acylated Single Chain Insulin - The invention is related to an acylated, single-chain insulin comprising the B- and the A-chain of human insulin or an analogue thereof connected by a connecting peptide, wherein a lysine residue being substituted for the natural amino acid residue in at least one of the positions B20, B21 or B22 in the human insulin B-chain is chemically modified by acylation. | 03-12-2009 |
20090099065 | Acylated Single Chain Insulin - The invention is related to an acylated, single-chain insulin comprising the B- and the A-chain of human insulin or an analogue thereof connected by a connecting peptide, wherein a lysine residue being substituted for the natural amino acid residue in one of the positions A12-A23 in the human insulin A-chain has been chemically modified by acylation. | 04-16-2009 |
20090123563 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand - Novel preparations comprising branched ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer. The preparations have a prolonged action designed for flexible injection regimes. | 05-14-2009 |
20090137454 | Insulin Derivatives - The present invention is related to insulin derivatives having a side chain attached to an ε-amino group of a Lys residue present in the A-chain or to an ε-amino group of a Lys residue in the B-chain. | 05-28-2009 |
20090143592 | Glucagon Antagonists/Inverse Agonists - A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity. | 06-04-2009 |
20090170750 | Single-Chain Insulin - The present invention is related to single-chain insulin having insulin activity comprising a B- and an A-chain or a modified B- and A-chain connected by a connecting peptide of from 6-11 amino acids. The single-chain insulins will have biological insulin activity and an IGF-1 receptor affinity similar to or lower than that of human insulin and a high physical stability. The single-chain insulin may contain at least one basic amino acid residues in the connecting peptide. The single-chain insulins may also be acylated in one or more Lys residues. | 07-02-2009 |
20100009899 | Novel Insulin Derivatives - The present invention relates to insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the α-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula: | 01-14-2010 |
20100216690 | Pegylated Single-Chain Insulin - The present invention is related to a single-chain insulin comprising the B- and the A-chain of human insulin or analogues thereof connected by a connecting peptide having from 3-35 amino acid residues, wherein the single-chain insulin comprises at least one PEG group attached to at least one lysine residue in the single-chain insulin molecule and/or to the B1 N terminal amino acid residue. The PEGylated single-chain insulins may comprise up to 4 PEG groups which may be the same or different. | 08-26-2010 |
20100216691 | Protease Stabilized, Pegylated Insulin Analogues - Novel PEGylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. The PEGylation is at B29K. | 08-26-2010 |
20100227796 | Insulin Derivatives - The present invention is related to insulin derivatives having a side chain attached either to the α-amino group of the N-terminal amino acid residue of B chain or to an ε-amino group of a Lys residue present in the B chain of the parent insulin molecule via an amide bond which side chain comprises one or more residues of ethylenglycol, propyleneglycol and/or butyleneglycol containing independently at each termini a group selected from —NH | 09-09-2010 |
20110039769 | INSULIN ALBUMIN CONJUGATES - Insulin albumin conjugates consisting of an insulin analogue, a bifunctional linker and albumin can efficiently be used to treat diabetic patients. | 02-17-2011 |
20110098439 | INSULINS WITH AN ACYL MOIETY COMPRISING REPEATING UNITS OF ALKYLENE GLYCOL CONTAINING AMINO ACIDS - Acylated insulins wherein an acyl moiety is attached to the parent insulin and wherein said acyl moiety comprises repeating units of alkylene glycol containing amino acids and wherein there is only one lysine residue (K & Lys) in the parent insulin have satisfactory properties when administered pulmonary. | 04-28-2011 |
20110098440 | Insulin Analogues with an Acyl and Alkylene Glycol Moiety - An acylated insulin analogue wherein the insulin analogue comprises a lysine residue connected C-terminally to the A21 amino acid residue or a peptide residue of up to 4 amino acid residues comprising a lysine residue which peptide residue is connected C-terminally to the A21 amino acid residue, characterized in that an acyl moiety comprising an alkylene glycol moiety is attached to the lysine residue in the A22 position or attached to a lysine residue present in the peptide residue that is attached to the C terminal end of the A21 amino acid residue and wherein there is only one lysine (K, Lys) in the insulin analogue, can conveniently be administered pulmonary. | 04-28-2011 |
20110105720 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES - Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. | 05-05-2011 |
20110213131 | Method of Acylating a Peptide or Protein - A method has for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described. | 09-01-2011 |
20120035104 | Insulin derivatives - The present invention relates to insulin derivatives having a side chain attached either to the α-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds. | 02-09-2012 |
20120071402 | Protease Stabilized, Pegylated Insulin Analogues - Novel PEGylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. The PEGylation is at B29K. | 03-22-2012 |
20120208749 | Insulin derivatives - The present invention is related to insulin derivatives having a side chain attached either to the α-amino group of the N-terminal amino acid residue of B chain or to an ε-amino group of a Lys residue present in the B chain of the parent insulin molecule via an amide bond which side chain comprises one or more residues of ethyleneglycol, propyleneglycol and/or butyleneglycol containing independently at each termini a group selected from —NH | 08-16-2012 |
20120245085 | Pharmaceutical Solution of Non Covalently Bound Albumin and Acylated Insulin - If albumin is added to a pharmaceutical formulation containing acylated insulin described in WO 2009/022005 and WO 2009/022013, the acylated insulin can be kept in solution after subcutaneous injection. | 09-27-2012 |
20130157938 | Insulin Derivatives Containing Additional Disulfide Bonds - The present invention is related to insulin derivatives containing additional disulfide bonds and methods of making such. | 06-20-2013 |
20140073564 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES - Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. | 03-13-2014 |
20140142280 | Method of Acylating a Peptide or Protein - A method for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described. | 05-22-2014 |
20140315797 | Novel N-Terminally Modified Insulin Derivatives - The invention is related to novel N-terminally modified insulin derivatives, pharmaceutical compositions comprising such and methods of making such. | 10-23-2014 |
20140349925 | NOVEL INSULIN DERIVATIVES - The present invention relates to insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the α-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula: | 11-27-2014 |
20140357838 | N-Terminally Modified Insulin Derivatives - The invention is related to novel N-terminally modified insulin derivatives comprising extra disulphide bond(s), pharmaceutical compositions comprising such and methods of making such. | 12-04-2014 |
20140371140 | Insulin derivatives Containing Additional Disulfide bonds - The present invention is related to insulin derivatives containing additional disulfide bonds and methods of making such. | 12-18-2014 |